Skip to content

Frequently Asked Questions

Find answers to the most common questions about Qlosi

Downwards arrow

Office Resources

Patients considering Qlosi? Preview this resource available for your office

Downwards arrow

Patient Resources

Help your patients learn about presbyopia and get started on Qlosi

Downwards arrow

Sign Up

Stay in the know about Qlosi

Downwards arrow

 

Frequently Asked Questions

Who would benefit most from Qlosi?
Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic receptor agonist indicated for the treatment of presbyopia in adults. The Qlosi clinical trials (NEAR-1 and NEAR-2) included patients who were between 45–64 years old, with mild-to-moderate presbyopia, and without prior refractive surgery or IOL implantation.1
How is Qlosi different from other eye drops for presbyopia?

Qlosi is the only FDA-approved presbyopia eye drop with the lowest effective concentration of pilocarpine for optimal results2,3

  • Pilocarpine, used at concentrations of 1% (10 mg/mL) or higher, has historically been used to treat glaucoma4
  • Qlosi contains 0.4% (4 mg/mL) of pilocarpine hydrochloride as the active ingredient2
How is Qlosi dosed?
Patients can choose 1 drop or 2 drops in each eye, giving them a flexible dosing solution for presbyopia. Qlosi can be taken daily. Patients can start by using one drop in each eye, and this can be repeated a second time after 2 to 3 hours.2
How soon can patients expect Qlosi to work?

On day 15, some Qlosi users achieved an improvement in their near vision within 20 minutes after administration of dose 1, which lasted up to 8 hours, without compromising distance vision1,2

  • After a second dose, patients experienced near vision improvement lasting out to 8 hours2
  • Patients achieved their best results when taking Qlosi consistently over 2 weeks1,2
How long does Qlosi last?
With both doses, the effects of Qlosi can last up to 8 hours.2 
Can Qlosi be used with other topical eye medications?
Qlosi can be used alongside other eye medications. Simply wait 5 minutes after using Qlosi before using the other eye drops.2
Can contact wearers use Qlosi?

Yes. Contact lens wearers can experience the benefits of Qlosi. Patients can simply remove them, use Qlosi, and wait 10 minutes before putting them back in.2

What are the most common side effects of Qlosi?
The majority of patients did not experience adverse effects (AEs) with Qlosi, and reported they were mild, transient, and self-resolving. The most commonly reported AEs were instillation site pain and headache 
(5%–8%).1,2
Who would not benefit from Qlosi?
Qlosi is not recommended to be used when iritis is present, and is contraindicated in patients with known hypersensitivity to the active ingredient. Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy.1,2
Will my patient’s insurance cover Qlosi?
Patients can pay for Qlosi out of pocket, as well as with funds from their Flexible Spending Account (FSA) and Health Savings Account (HSA) plans.

 

 

 

Sign Up Form

Important Safety Information

Expand

Indication and Usage

 

Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic receptor agonist indicated for the treatment of presbyopia in adults.

 

Important Safety Information

Contraindications

Hypersensitivity

 

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

 

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

 

Qlosi is not recommended to be used when iritis is present.

 

Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the installation of Qlosi and wait 10 minutes before reinsertion.

 

Avoid touching the tip of the vial to the eye or any other surface.

 

Adverse Reactions

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

 

Please see full Prescribing Information here: qlosi.com/prescribing-information

References

  1. Holland E, Karpecki P, Fingeret M, et al. Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005
  2. Qlosi [package insert]. Ponte Verda, FL. Orasis Pharmaceuticals.
  3. VUITY PI [package insert]. North Chicago, IL: AbbVie Inc.
  4. Singh P. The Return of Pilocarpine. Reflections on uses past and present. Glaucoma Today. 2002.